2-[7-(1,3-Benzodioxol-5-yl)-9-hydroxy-2-tetracyclo[8.2.1.03,12.06,11]trideca-4,7-dienyl]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2-[7-(1,3-Benzodioxol-5-yl)-9-hydroxy-2-tetracyclo[8.2.1.03,12.06,11]trideca-4,7-dienyl]acetic acid
• 化学式: C₂₂H₂₂O₅
• 分子量: 366.4
• InChiKey: XYHDKVJBIKILGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Method for the diagnosis, prognosis and treatment of lung cancer metastasis
  申请人：Fundació Institut de Recerca Biomèdica (IRB Barcelona)

  公开号：US10006091B2

  公开（公告）日：2018-06-26

  The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.

  本发明涉及肺癌转移的诊断或预后方法，该方法包括确定原发肿瘤样本中 c-MAF 基因是否扩增。同样，本发明还涉及一种诊断或预后肺癌转移的方法，以及一种确定相对于其他器官转移的骨转移倾向的方法，该方法包括确定 c-MAF 基因的表达水平。最后，本发明涉及使用 c-MAF 抑制剂作为治疗肺癌的靶点。
• Method for the diagnosis, prognosis and treatment of breast cancer metastasis
  申请人：FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)

  公开号：US11072831B2

  公开（公告）日：2021-07-27

  The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER− breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER− breast cancer metastasis.

  本发明涉及一种诊断或预后乳腺癌转移的方法，该方法包括确定原发肿瘤样本中 c-MAF 基因是否扩增。同样，本发明还涉及一种诊断或预后ER-乳腺癌转移的方法，以及一种确定骨转移与其他器官转移倾向的方法，其中包括确定c-MAF基因的表达水平。最后，本发明涉及使用 c-MAF 抑制剂作为治疗 ER- 乳腺癌转移的治疗靶点。
• METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS
  申请人：Fundació Institut de Recerca Biomèdica (IRB Barcelona)

  公开号：EP2626431B1

  公开（公告）日：2015-09-16
• Method for the Diagnosis, Prognosis and Treatment of Breast Cancer Metastasis
  申请人：Gomis Roger

  公开号：US20140057796A1

  公开（公告）日：2014-02-27

  The present invention relates to a method for the diagnosis or the prognosis of metastasis in breast cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in ER− breast cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the ER− breast cancer metastasis.
• METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS
  申请人：Institució Catalana de Recerca i Estudis Avançats

  公开号：US20140314792A1

  公开（公告）日：2014-10-23

  This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of the expression level of one or more genes whose expression is modulated by an increase in c-MAF expression. It also describes a method for the identification of marker genes with a propensity for metastatic cancer based on inducing the modulation of the c-MAF expression Finally, the use of PTHLH and PODXL inhibitors and RERG activators in the treatment and/or prevention of the cancer, in particular breast, colon, lung, kidney and thyroid cancer.